Effectiveness of SARS-CoV-2 vaccines on hemodialysis patients in Japan : A nationwide cohort study
© 2022 International Society for Apheresis and Japanese Society for Apheresis..
INTRODUCTION: This study compared the outcomes of dialysis patients who received SARS-CoV-2 vaccine with those who did not use data from the Japanese COVID-19 registry.
METHODS: A total of 1260 dialysis patients with confirmed positive SARS-CoV-2 infection was included in this study. Patients were divided into two groups: patients who experienced breakthrough infection and those who were unvaccinated. The need of oxygen supplementation and mortality risks were compared using multivariate logistic regression analysis.
RESULTS: The mortality rate was 24.2% in unvaccinated patients and 8.6% in breakthrough patients. The odds ratio of need of oxygen supplementation in the breakthrough patients relative to unvaccinated patients was 0.197. The hazard ratio of mortality in the breakthrough patients relative to unvaccinated patients was 0.464.
CONCLUSION: Our prospective observational study showed that SRAS-CoV-2 vaccination in hemodialysis patients is vital for reducing need of oxygen supplementation and mortality risk.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:27 |
|---|---|
| Enthalten in: |
Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy - 27(2023), 1 vom: 28. Feb., Seite 19-23 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Kikuchi, Kan [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Breakthrough infection |
|---|
| Anmerkungen: |
Date Completed 04.01.2023 Date Revised 11.01.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1111/1744-9987.13887 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM341331562 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM341331562 | ||
| 003 | DE-627 | ||
| 005 | 20231226011530.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1111/1744-9987.13887 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1137.xml |
| 035 | |a (DE-627)NLM341331562 | ||
| 035 | |a (NLM)35610734 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Kikuchi, Kan |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Effectiveness of SARS-CoV-2 vaccines on hemodialysis patients in Japan |b A nationwide cohort study |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 04.01.2023 | ||
| 500 | |a Date Revised 11.01.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2022 International Society for Apheresis and Japanese Society for Apheresis. | ||
| 520 | |a INTRODUCTION: This study compared the outcomes of dialysis patients who received SARS-CoV-2 vaccine with those who did not use data from the Japanese COVID-19 registry | ||
| 520 | |a METHODS: A total of 1260 dialysis patients with confirmed positive SARS-CoV-2 infection was included in this study. Patients were divided into two groups: patients who experienced breakthrough infection and those who were unvaccinated. The need of oxygen supplementation and mortality risks were compared using multivariate logistic regression analysis | ||
| 520 | |a RESULTS: The mortality rate was 24.2% in unvaccinated patients and 8.6% in breakthrough patients. The odds ratio of need of oxygen supplementation in the breakthrough patients relative to unvaccinated patients was 0.197. The hazard ratio of mortality in the breakthrough patients relative to unvaccinated patients was 0.464 | ||
| 520 | |a CONCLUSION: Our prospective observational study showed that SRAS-CoV-2 vaccination in hemodialysis patients is vital for reducing need of oxygen supplementation and mortality risk | ||
| 650 | 4 | |a Observational Study | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a SARS-CoV-2 | |
| 650 | 4 | |a SARS-CoV-2 vaccine | |
| 650 | 4 | |a breakthrough infection | |
| 650 | 4 | |a dialysis | |
| 650 | 7 | |a COVID-19 Vaccines |2 NLM | |
| 650 | 7 | |a Oxygen |2 NLM | |
| 650 | 7 | |a S88TT14065 |2 NLM | |
| 700 | 1 | |a Nangaku, Masaomi |e verfasserin |4 aut | |
| 700 | 1 | |a Ryuzaki, Munekazu |e verfasserin |4 aut | |
| 700 | 1 | |a Yamakawa, Tomoyuki |e verfasserin |4 aut | |
| 700 | 1 | |a Yoshihiro, Ota |e verfasserin |4 aut | |
| 700 | 1 | |a Hanafusa, Norio |e verfasserin |4 aut | |
| 700 | 1 | |a Sakai, Ken |e verfasserin |4 aut | |
| 700 | 1 | |a Kanno, Yoshihiko |e verfasserin |4 aut | |
| 700 | 1 | |a Ando, Ryoichi |e verfasserin |4 aut | |
| 700 | 1 | |a Shinoda, Toshio |e verfasserin |4 aut | |
| 700 | 1 | |a Wakino, Shu |e verfasserin |4 aut | |
| 700 | 1 | |a Nakamoto, Hidetomo |e verfasserin |4 aut | |
| 700 | 1 | |a Takemoto, Yoshiaki |e verfasserin |4 aut | |
| 700 | 1 | |a Akizawa, Tadao |e verfasserin |4 aut | |
| 700 | 0 | |a COVID-19 Task Force Committee of the Japanese Association of Dialysis Physicians, the Japanese Society for Dialysis Therapy, and the Japanese Society of Nephrology |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy |d 2003 |g 27(2023), 1 vom: 28. Feb., Seite 19-23 |w (DE-627)NLM126443165 |x 1744-9987 |7 nnns |
| 773 | 1 | 8 | |g volume:27 |g year:2023 |g number:1 |g day:28 |g month:02 |g pages:19-23 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1111/1744-9987.13887 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 27 |j 2023 |e 1 |b 28 |c 02 |h 19-23 | ||